CTRI/2022/02/040402CompletedPhase 3
Comparison of oral tamoxifen. versus centchromon in reducing the size of breast fibroadenoma in adolescent and middle aged ladies
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •FNAC proven breast fibroadenoma of size < 5 cm
Exclusion Criteria
- •1. Past history of carcinoma breast
- •2. Family history of carcinoma breast in 1st degree relatives
- •3. History of PCOD, cervical dysplasia, and liver disease
- •4. Pregnancy and Lactating ladies
- •5. Recurrent fibroadenoma
- •6. Fibroadenoma associated with cellular atypic
- •7. Ladies planning pregnancy during the study period
- •8. BMI >35 kg/m2
- •9. Baseline endometrial thickness > 12 mm
Investigators
Similar Trials
Completed
Phase 4
Comparing effectiveness of Centchroman and Tamoxifen in mastalgia: a randomised control trialCTRI/2021/01/030206AIIMS Bhubaneswar56
Recruiting
Unknown
Centchroman vs tamoxifen in patients with breast paiCTRI/2023/11/059992on-funded
Unknown
Phase 3
A clinical trial to study the effects of two drugs, Centchroman versus Tamoxifen in patients with breast pain and non-cancerous breast lumps.CTRI/2016/05/006905Intra Mural Grant from All India Institute of Medical Sciences New Delhi200
Not yet recruiting
Phase 4
A study to find best medicine and its dose for the treatment of breast pain.CTRI/2018/02/012043HLL lifecare Ltd
Completed
Phase 2
Comparison of adding Tamoxifen or Gonadotropin to Clomiphene for induction ovulation in Polycystic Ovary Syndrome (PCOS) patients resistance to ClomiphenePolycystic Ovary Syndrome.Polycystic Ovary SyndromeIRCT138904121760N8Vice Chancellor for Research and Technology, Babol University of Medical Sciences200